Thank you. This post has been successfully flagged as inappropriate. If warranted, appropriate action will be taken
Thank you. This comment has been successfully flagged as inappropriate. If warranted, appropriate action will be taken

Sign up | login
docpid


Post

Respiratory Syncytial Virus (RSV) Prophylaxis



Palivizumab (Synagis) is the only product on the American market for use in infants at high risk for adverse outcomes of a respiratory syncytial virus (RSV) infection.

Palivizumab is a humanized mouse monoclonal antibody and has the benefit of being administrated intramuscularly rather than intravenously.

Palivizumab is given in five (maximum) monthly IM injections during RSV season (usually November through March or April depending on the region) and is generally well tolerated.

Palivizumab has shown to be safe and effective in reducing RSV hospitalizations in high-risk infants by 39% to 82%.

Palivizumab is an expensive drug; therefore, it is only recommended for high-risk infants.

 

RSV prophylaxis should be considered for the following infants:

  • Infants born before 29 weeks during RSV season. They should be given prophylaxis until 12 months of age.
  • Children born prematurely at or before 32 weeks who are younger than 2 years old with chronic lung disease (CLD) and who required treatment for their CLD within 6 months of the onset of RSV season (including oxygen therapy).
  • Infants up to 12 months old with hemodynamically significant cyanotic or complicated congenital heart disease.
  • Infants up to 12 months old with neuromuscular disorder or congential anomalities that compromise clearing of respiratory secretions.

 

Once opened, a vial of palivizumab must be used within 6 hours (there is no preservative). It can be given concurrently with vaccines.

Always consult the American Academy of Pediatrics (AAP) or the CDC for the most current and specific recommendations of the adminstration of palivizumab, including the length of treatment.



Tags of Post: Respiratory syncytial virus, RSV, prophylaxis, Palivizumab

Author: Health Awareness

Published on Jan. 7, 2019

10 views

Report Post

Unwanted commercial content or spam
Sexually explicit material
Hate speech or graphic violence
Harrassment or bullying


|

Are you sure you want to delete this post?





|
0 followers
2 | 0

0 comments



Comment







Title Successfully Changed
The tags have been successfully changed
Post Successfully Edited
Comment Edited Successfully
Comment Posted Successfully
The comment has been successfully deleted




Home | Posts | Documents | Users | Public Pages | Contact